Compare · LUNG vs RMD
LUNG vs RMD
Side-by-side comparison of Pulmonx Corporation (LUNG) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNG and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 317.9x LUNG ($107.4M).
- RMD has been more active in the news (9 items in the past 4 weeks vs 2 for LUNG).
- RMD has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- Pulmonx Corporation
- ResMed Inc.
- Price
- -
- -
- Market cap
- $107.4M
- $34.13B
- 1M return
- -
- +12.44%
- 1Y return
- -
- -17.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 2
- 9
- Recent ratings
- 17
- 25
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest LUNG
- Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation
- SEC Form 10-Q filed by Pulmonx Corporation
- Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pulmonx Reports Second Quarter 2026 Financial Results
- Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
- Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
- Director Burns Thomas William was granted 40,000 shares, increasing direct ownership by 54% to 113,399 units (SEC Form 4)
- Director Ferrari Richard was granted 40,000 shares, increasing direct ownership by 46% to 127,024 units (SEC Form 4)
- Director Florin Daniel P was granted 40,000 shares, increasing direct ownership by 43% to 133,910 units (SEC Form 4)
- Director Melenikiotou Georgia was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)